Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 5/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 9/20 | 0.41 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | SMG1 | Q96Q15 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12720064 | 0.88 | F2R (0.51) | F2RCNR1TMEM97ABL1BCR | |
| SCHEMBL641746 | 0.87 | F2R (0.54) | F2RCNR1TMEM97ABL1BCR | |
| SCHEMBL12720271 | 0.86 | F2R (0.51) | F2RCNR1TMEM97SCN9A | |
| SCHEMBL12720001 | 0.85 | F2R (0.49) | F2RCNR1TMEM97ABL1BCR | |
| SCHEMBL13808345 | 0.85 | F2R (0.43) | F2RCNR1TMEM97ABL1BCR | |
| SCHEMBL12720565 | 0.82 | F2R (0.50) | F2RCNR1TMEM97 | |
| SCHEMBL12720003 | 0.81 | F2R (0.51) | F2RCNR1TMEM97ABL1BCR | |
| SCHEMBL12720072 | 0.81 | F2R (0.49) | F2RCNR1TMEM97ABL1BCR | |
| SCHEMBL12720124 | 0.81 | F2R (0.55) | F2RCNR1TMEM97ABL1BCR | |
| SCHEMBL12719955 | 0.81 | F2R (0.50) | F2RCNR1TMEM97ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |